

## **Together We Can Control High Blood Pressure**

#### Sonia Angell, MD, MPH

Senior Advisor for Global Noncommunicable Diseases

PAHO World Health Day Celebration April 5, 2013



Center for Global Health

Office of the Director

#### The Call to Act is Global, the Time to Act is Now

WHO Global Monitoring Framework with targets and indicators Set of 9 voluntary global NCD targets for 2025 nore NGD **Normful use** a'n redact Essential NCD of alcohol excitations and 10% reduction technologies. 10% coveras Physical Inactivity 10% reduction Drug therapy and councileg SDAi coverbo 540 sodium intake 30% reduction Diabetes obisity 0% increase **Rated blood** Tobarco ass presture 10% reduction 25% reduction

By 2025 the prevalence of raised blood pressure will be reduced by 25%

# **Costs of Hypertension**

#### Global

- Hypertension cost \$372 billion (US) in 2001
- 10% of the overall healthcare expenditures
- Latin America and the Caribbean
  - Direct healthcare costs were \$10.6 billion in 2001
- If blood pressure levels remain unchanged, healthcare costs over the next 10 years are estimated to be . . .
  - \$1 trillion globally
  - \$43 billion in Latin America and the Caribbean

<sup>\*</sup> Source: Gaziano TA, et al. J Hypertens 2009;27:1472-1477.

# Hypertension in Latin America and the Caribbean

- □ **Prevalence** 11 43%
- □ Awareness 12 71%
- □ Treatment 10 88%
- **Control 5 58%**
- Global hypertension prevalence: 40%
  1 billion people worldwide

Source: Ordúñez P, et al. Pan Am J Public Health 2001;10:226-231; Mendis S, Puska P, Norrving B, editors. Global atlas on cardiovascular disease prevention and control. Geneva, Switzerland: World Health Organization; 2011. Available from: whqlibdoc.who.int/publications/2011/9789241564373\_eng.pdf.



# **Hypertension Treatment Considerations**

#### Barriers to medication adherence

- Availability
- Affordability
- Complexity

#### Barriers to effective treatment delivery

- Complicated treatment algorithms for providers
- Inadequate patient follow-up (frequency and care organization)






## Building on Lessons Learned from Tuberculosis

- Structured approach
- High quality standardized care
  - Accountable for each patient and outcome
  - Targets and indicators
  - Data collection, evaluation, and reporting
- Targets and indicators define further actions and additional indicators
  - Expansion of services
  - Identifying and treating more patients
  - Reducing the burden of disease

#### **Opportunities in Pharmacologic Treatment of HTN**

#### Standardize, Simplify.



# **Call to Action**

- Effective treatment has potential to significantly improve global population health
- Development of a strategy and framework for standardizing the pharmacologic treatment of hypertension that is both feasible and flexible to have worldwide applicability
- Development of a strategy and framework that acknowledges and supports use of existing evidenced-based guidelines for diagnosis and treatment of hypertension

# Global Standardized Hypertension Treatment Initiative

#### Purpose


 To support the development of a strategy and framework for standardizing hypertension medication treatment to have worldwide applicability

#### Regional collaboration to start

- Pan American Health Organization (PAHO)
- Centers for Disease Control and Prevention
- Key stakeholders and organizations across the Americas



## The Vision of Hypertension Control Globally



#### For more information please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333 Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348 E-mail: cdcinfo@cdc.gov Web: http://www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



Center for Global Health Office of the Director